Golimumab Trough Levels in Patients With Ulcerative Colitis
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
MRD-guided Treatment in NPM1mut AML Patients
- Status
- TERMINATED
- Phase
- PHASE2
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.
- Status
- TERMINATED
- Phase
- PHASE4
Effect of Different Ovarian Stimulation Protocols on Endometrial Receptivity
- Status
- COMPLETED
- Phase
- PHASE4
Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Trial of Pembrolizumab in Cancer of Unknown Primary
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002)
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
- Status
- WITHDRAWN
- Phase
- PHASE1
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
- Status
- COMPLETED
- Phase
- PHASE3
Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)
- Status
- TERMINATED
- Phase
- PHASE1
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2